Phase II trial of recombinant interferon-α with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma

Melanoma Research

Volumn 5, Issue 4, 1995, Pages 273-276

  Feun, L G ^a   Savaraj, N ^a   Moffat, F ^a   Robinson, D ^a   Liebmann, A ^a   Hurley, J ^a   Raub, W A ^a   Richman, S P ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Interferon; Melanoma

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA INTERFERON; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; INTERFERON TYPE I, RECOMBINANT; MALE; MELANOMA; MIDDLE AGE; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0029040035     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/00008390-199508000-00011     Document Type: Article

References (17)

1. McClay FF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma in Sem. Oncology 1998; 15: 569-577.
2. Legha S. Interferon in the treatment of malignant melanoma. Biother Cancer 1988; 1: 1-5.
3. Wadler S, Schwartz E. Interferon as modulator of cytotoxic drugs. Medguide Oncol 1990; 10.
4. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1953; 53: 457-481.
5. Namba M, Yamaolo S, Tanaka H, et al. In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells, Cancer 1984; 54: 2262-2267.
6. Carmicheal J, Ferguson RJ, Wolf CR, et al. Augmentation of cytotoxicity of chemotherapy by human alpha interferon in humun non-small cell lung cancer xenografts. Cancer Res 1986; 46: 1916-1920.
7. Vorobiol DA, Falkson G, Voges CW. DTIC Versus DTIC and recombinant interferon alfa 26 GIFN α 260 in the treatement of the patients (pts) with advanced malidnant melanoma (mm). Proc Am Soc Clin Oncol 1989; 8: 284 (abstract).
8. Falkson CI, Falkson H, Falkson HC. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-1408.
9. Smith J, Ferguson R, Stewart M, et al. Alpha interferon potentiates cisplatin in patients with non-small cell lung cancer. Proc Am Soc Clinic Oncol 1988; 7: 201 (abstract).
10. Saito T, Verens ME, Welarden CE. Interferon and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay, Cancer Chemother Pharmacol 1987; 19: 233-239.
11. Kuebler JP, Borden FC, Bryan GY, et al. In litro growth inhibition ot human renal cell carcinoma (RCC) in the presence of recombinant interteron-b (IFN-B) and vinblastine (V). Proc Am Assoc Cancer Res 1985; 26: 322.
12. Legha S. Interferon in the treatment ot malignant melanoma. Biother Cancer 1988, 1: 1-5.
13. Schultz M, Poo WJ, Buzand AC. A phase II study of cisplatin (CDDP), dacarbazine (DTIC) carmustine (BCNU), tamoxifen (TM) and interferon α2β (α IFN) in metastatic melanoma. Proc Am Soc Clin Oncol 1993; 12: 390.
14. Legha SS, Ring S, Papdopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and dacarbazine (CVD) for metastatic melanoma, Cancer 1989; 64: 2024-2029.
15. Pyrhonen S, Hahka-Keimppinen M, Mulmnen T. A promising interferon plus four-drug chemotherapy regimen tor metastatic melanoma. J Clin Oncol 1992; 10: 1919-1926.
16. Richard JM, Mehla N, Ramming R, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
17. Legha S, Buzaici AC, Ring S, et al. Improved results of treatment of metastatic melanoma with combined use of biotherapv and chemotherapy (Biochem). Proc Am Soc Clin Oncol 1994; 13: 394.